このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Shanghai Junshi Biosciences マネジメント

マネジメント基準チェック /24

Shanghai Junshi Biosciences'の CEO はCong Liで、 Nov2021年に任命され、の在任期間は 2.58年です。の年間総報酬はCN¥ 4.22Mで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.013%を直接所有しており、その価値はHK$ 3.42M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と6年です。

主要情報

Cong Li

最高経営責任者

CN¥4.2m

報酬総額

CEO給与比率	100.0%
CEO在任期間	2.7yrs
CEOの所有権	0.01%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	5.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Shanghai Junshi Biosciences の収益と比較して、Cong Li の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥4m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥3b
Dec 31 2022	CN¥4m	CN¥4m	-CN¥2b

報酬と市場: Congの総報酬 ($USD 581.18K ) は、 Hong Kong市場 ($USD 446.31K ) の同規模の企業の平均を上回っています。

報酬と収益: Congの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Cong Li (60 yo)

2.7yrs

在職期間

CN¥4,224,000

報酬

Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.5b
Cong Li	Co-CEO & Executive Director	2.7yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	less than a year	CN¥5.86m	データなし
Ning Li	Executive Vice-Chairman of the Board	6.1yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Baohong Xu	Financial Director	3.7yrs	CN¥2.73m	0.00071% CN¥ 187.9k
Zhuobing Zhang	Deputy GM & Executive Director	no data	CN¥8.13m	0.88% CN¥ 232.4m
Sheng Yao	Senior VP & Executive Director	no data	CN¥8.01m	データなし
Gang Wang	Deputy GM	4.9yrs	CN¥1.32m	0.0010% CN¥ 269.9k
Xin Li	Executive Director	less than a year	データなし	0.0096% CN¥ 2.6m
Lu Yuan	Assistant to GM & Chief of Internal Audit Department	3.7yrs	データなし	データなし
Qian Wei	Chief Commercial Officer	3yrs	データなし	データなし
Patricia Keegan	Chief Medical Officer	no data	データなし	データなし

2.8yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: 1877の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.5b
Cong Li	Co-CEO & Executive Director	7.6yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	2.1yrs	CN¥5.86m	データなし
Ning Li	Executive Vice-Chairman of the Board	6.1yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Zhuobing Zhang	Deputy GM & Executive Director	7.6yrs	CN¥8.13m	0.88% CN¥ 232.4m
Sheng Yao	Senior VP & Executive Director	7.6yrs	CN¥8.01m	データなし
Gang Wang	Deputy GM	less than a year	CN¥1.32m	0.0010% CN¥ 269.9k
Xin Li	Executive Director	less than a year	データなし	0.0096% CN¥ 2.6m
Yi Tang	Non-Executive Director	9.2yrs	データなし	0.74% CN¥ 195.7m
Chun Zhang	Independent Non-Executive Director	4.1yrs	CN¥200.00k	データなし
Xiaoyuan Feng	Independent Non-Executive Director	2.6yrs	CN¥200.00k	データなし
Hongyan Kuang	Chairman of the Board of Supervisors	less than a year	データなし	データなし

5.1yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: 1877の取締役会は経験豊富であると考えられます ( 6年の平均在任期間)。

Shanghai Junshi Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Recent updates

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab

Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab

Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration

Third quarter 2022 earnings released: CN¥0.75 loss per share (vs CN¥0.50 loss in 3Q 2021)

Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: CN¥0.57 loss per share (vs CN¥0.37 loss in 2Q 2021)

Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration

Forecast to breakeven in 2024

マネジメント基準チェック /24